Happy Employee Appreciation Day to Team Enanta! We are very grateful for our dedicated, passionate, and fun team who work relentlessly in an effort to achieve our vision of transforming the lives of patients with viral infections and immunological diseases with curative therapies. Today and every day, we appreciate your commitment, wisdom and passion. Looking forward to celebrating with lunch on Monday! #EmployeeAppreciation
Enanta Pharmaceuticals
生物技术研究
Watertown，MA 10,011 位关注者
Our vision is to transform the lives of patients with curative therapies.
关于我们
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET? (U.S.) and MAVIRET? (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
- 网站
-
https://www.enanta.com
Enanta Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Watertown，MA
- 类型
- 上市公司
- 领域
- Virology和Immunology
地点
-
主要
获取路线
500 Arsenal Street
US，MA，Watertown，02472
Enanta Pharmaceuticals员工
动态
-
In advance of tomorrow’s International Women's Day 2025, all of us at Enanta want to do our part to #AccelerateAction. According to data from the World Economic Forum, as the current rate of progress, it will take until 2158, which is roughly five generations from now, to reach full gender parity. At Enanta, we are committed to helping achieve gender equality in the workforce and to improving the rate of progress. #IWD2025 #AccelerateAction
-
-
On this International Day of Women and Girls in Science, we recognize some of Enanta's female scientists and ask them what they would tell their younger self about a career in science. Here are their thoughts. #WomeninScience
-
This afternoon we announced our fiscal first quarter 2025 financial results and pipeline update. To read the release, click here: https://lnkd.in/dzmDfSzf
-
Happy Lunar New Year from all of us at Enanta! Yesterday, we came together to celebrate the Year of the Snake which symbolizes good luck and rebirth. We hope this year brings everyone good fortune!?#LunarNewYear2025
-
-
Last Wednesday marked what would have been Dr. Martin Luther King Jr.’s 95th birthday. We commemorate his life, legacy, and steadfast commitment to fighting for freedom, civil rights, and equality for all people. #MLKDay2025
-
-
In case you missed it, our President & Chief Executive Officer, Jay R. Luly, Ph.D., presented at the J.P. Morgan 43rd Annual Healthcare Conference this morning. He outlined our key catalysts for 2025 and was joined by our Chief Product Strategy Officer Tara Kieffer, Ph.D., for Q&A. To listen to the replay, visit here: https://lnkd.in/ehhcu5iv #JPM2025
-
-
Our President and Chief Executive Officer, Jay R. Luly, Ph.D., will present at the J.P. Morgan Healthcare Conference on Wednesday, January 15 at 8:15 am PT / 11:15 am ET. He will be joined by Tara Kieffer, Ph.D., during the Q&A portion of the presentation. https://lnkd.in/etX-cZNz
-
-
As 2024 comes to an end, we reflect on the progress we’ve made this year and look forward to a successful 2025. Enanta’s offices will be closed for the holidays to allow our team to rest and recharge before we begin another important year ahead! We wish everyone a wonderful holiday season filled with joy and relaxation. #HappyHolidays #TheEnantaExperience
-
-
This morning, we announced positive data from our first-in-pediatrics Phase 2 study evaluating our N-protein inhibitor, zelicapavir, for the treatment of RSV. To read the release click here: https://lnkd.in/etugwwUz